Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225 Ac-PSMA-617.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 37796187.
- Also identified by DOI 10.1097/RLU.0000000000004843.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
177 Lu-prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer has emerged as a very promising therapy. However, some of the PSMA-expressing positive metastatic castration-resistant prostate cancer patients never respond or develop resistance to 177 Lu-PSMA. We present a case of castration-resistant prostate cancer with multiple bone metastases. Remission of clinical symptoms and imaging lesions can be observed after 4 cycles of 225 Ac-PSMA-617 therapy. Moreover, the man did not have any observable adverse effects.
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant
- Bone Neoplasms